The intricate molecular pathways governing cancer development and progression have
spurred intensive investigations into novel therapeutic targets. Glycogen Synthase Kinase-3 …

Rapid technical advances in DNA sequencing and genome-wide association studies are
driving the discovery of the germline and somatic mutations that are present in different …

Renal cell carcinoma (RCC), the most lethal type of genitourinary cancer, is generally
resistant to chemotherapy and radiation therapy. Surgical excision of the tumor at a localized …

MET and its ligand HGF are involved in many biological processes, both physiological and
pathological, making this signaling pathway an attractive therapeutic target in oncology …

Background Activation of the c-Met pathway occurs in a range of malignancies, including
papillary renal cell carcinoma (RCC). Its activity in clear cell RCC is less clear. We …

Background Cabozantinib targets tyrosine kinases including the hepatocyte growth factor
receptor (MET) and vascular endothelial growth factor (VEGF) receptor 2, which are …

Cabozantinib inhibits receptor tyrosine kinases involved in tumor angiogenesis and
metastasis. The capsule formulation (Cometriq®) is approved for the treatment of …

Renal cell carcinoma (RCC) represents 85–95% of kidney cancers and is the most frequent
type of renal cancer in adult patients. It accounts for 3% of all cancer cases and is in 7th …

About one-third of patients with advanced renal cell carcinoma (RCC) have bone metastasis
that are often osteolytic and cause substantial morbidity, such as pain, pathologic fracture …

The scatter factor/hepatocyte growth factor (HGF)-c-Met axis is involved in the malignant
phenotype of various tumor types via activation of a wide range of autocrine and paracrine …